The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC

References

• Grattendick KJ, Nakashima JM, Feng L, Giri SN, Marqolin SB. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol 2008;8:679–687.
   PubMed Web of Science ®Google Scholar
• Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008;76:275–282.
   PubMed Web of Science ®Google Scholar
• Sheppeck JE 2nd, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Let 2007;17:1413–1417.
   PubMed Web of Science ®Google Scholar
• Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, TrzaskosJ Duan, JJ. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1’ substituents. Bioorg Med Chem Let 2008;18:1958–1962 .
   PubMed Web of Science ®Google Scholar
• Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999;878:442–452.
   PubMed Web of Science ®Google Scholar
• Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochem 2002;41:9462–9469.
   PubMed Web of Science ®Google Scholar
• Sheppeck JE 2nd, Tebben A, Gilmore JL, Yang A, Wasserman ZR, Decicco CP, Duan JJ. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. Bioorg Med Chem Let 2007;17:1408–1412.
   PubMed Web of Science ®Google Scholar
• Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003;34:2165–70.
   PubMed Web of Science ®Google Scholar
• Jin G, Huang X, Black R, Wolfson M, Rauch C, McGregor H, Ellestad G, Cowling R. A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme. Anal Biochem 2002;302:269–275.
   PubMed Web of Science ®Google Scholar
• Neumann U, Kubota H, Frei K, Ganu V, Leppert D. Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem 2004;328:166–173.
   PubMed Web of Science ®Google Scholar
• Doedens JR, Mahimkar RM, Black RA. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem Biophys Res Commun 2003;308:31–338.
   Web of Science ®Google Scholar
• Niu X, Umland S, Ingram R, Beyer BM, Liu YH, SunJ Lundell, D, Orth P. IK682, a tight binding inhibitor of TACE. Arch Biochem Biophys 2006;451:43–50.
   PubMed Web of Science ®Google Scholar
• Lee MH, Rapti M, Murphy G. Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme. J Biol Chem 2004;279:45121–45129.
   PubMed Web of Science ®Google Scholar
• Leppert D, Lindberg RLP, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in bacterial meningitis and multiple sclerosis. Brain Res Rev 2001;36:249–257.
   PubMed Web of Science ®Google Scholar
• Lee MH, Verma V, Maskos K, Nath D, Knauper V, Dodds P, Amour A, Murphy G. Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J 2002;364:227–234.
   PubMed Web of Science ®Google Scholar
• Lee MH, Maskos K, Knauper V, Dodds P, Murphy G. Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Protein Sci 2002;11:2493–2503
   PubMed Web of Science ®Google Scholar
• Galazka G, Windsor LJ, Birkedal-Hansen H, Engler JA. APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. Biochem 1996;35:11221–11227.
   PubMed Web of Science ®Google Scholar
• Chun K, Park SK, Kim HM, Choi Y, Kim MH, Park CH, Joe BY, Chun TG, Choi HM, Lee HY, Hong SH, Kim MS, Nam KY, Han G. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem 2008;16:530–535.
   PubMed Web of Science ®Google Scholar